Endpoint selection in HER2-positive early breast cancer

Affiliations

¹ Division of Medical Oncology, Princess Magaret Cancer Centre and the University of Toronto, Toronto ON, M5G 2M9, Canada. Electronic address: eitan.amir@uhn.ca.

Comment

Eitan Amir. Lancet Oncol. 2019 Mar.

. 2019 Mar;20(3):315-316.

doi: 10.1016/S1470-2045(18)30779-4. Epub 2019 Jan 29.

¹ Division of Medical Oncology, Princess Magaret Cancer Centre and the University of Toronto, Toronto ON, M5G 2M9, Canada. Electronic address: eitan.amir@uhn.ca.

No abstract available

Comment on

Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis.
Saad ED, Squifflet P, Burzykowski T, Quinaux E, Delaloge S, Mavroudis D, Perez E, Piccart-Gebhart M, Schneider BP, Slamon D, Wolmark N, Buyse M. Saad ED, et al. Lancet Oncol. 2019 Mar;20(3):361-370. doi: 10.1016/S1470-2045(18)30750-2. Epub 2019 Jan 29. Lancet Oncol. 2019. PMID: 30709633 Free PMC article.